THRD241220C25000
- 0.00
- 0.000.00%
Third Harmonic Bio Newsroom
Stifel Maintains Third Harmonic Bio(THRD.US) With Buy Rating, Maintains Target Price $23
Third Harmonic Bio, Inc. (THRD) Receives a Buy From Stifel Nicolaus
Morgan Stanley Maintains Third Harmonic Bio(THRD.US) With Buy Rating, Maintains Target Price $20
Morgan Stanley Maintains Third Harmonic Bio(THRD.US) With Buy Rating, Maintains Target Price $20
Analysts Are Bullish on Top Healthcare Stocks: Third Harmonic Bio, Inc. (THRD), Collegium Pharmaceutical (COLL)
TD Cowen Maintains Third Harmonic Bio(THRD.US) With Buy Rating
TD Cowen Remains a Buy on Third Harmonic Bio, Inc. (THRD)
Buy Rating Affirmed for Third Harmonic Bio Amidst Promising Clinical Developments and Market Prospects
Third Harmonic Bio Analyst Ratings
Morgan Stanley Upgrades Third Harmonic Bio to Overweight, Raises Price Target to $20
Buy Rating Justified by Third Harmonic Bio's Promising Drug THB335 and Swift Clinical Advancements
Analysts Offer Insights on Healthcare Companies: Aytu BioScience (AYTU), Madrigal Pharmaceuticals (MDGL) and Third Harmonic Bio, Inc. (THRD)
Third Harmonic Bio Analyst Ratings
Third Harmonic Bio Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Third Harmonic Bio, Inc. (THRD), Treace Medical Concepts (TMCI)
Morgan Stanley Maintains Equal-Weight on Third Harmonic Bio, Raises Price Target to $7
Third Harmonic Bio Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Third Harmonic Bio, Inc. (THRD) and Verve Therapeutics (VERV)
LifeSci Capital Upgrades Third Harmonic Bio, Inc. (THRD) to a Buy
LifeSci Capital Sticks to Its Hold Rating for Third Harmonic Bio, Inc. (THRD)